Comprehensive Physiology Wiley Online Library

Thyroid Hormone, Hormone Analogs, and Angiogenesis

Full Article on Wiley Online Library



ABSTRACT

Modulation by thyroid hormone and hormone analogs of angiogenesis in the heart after experimental infarction, and in other organs, has been appreciated for decades. Description of a plasma membrane receptor for thyroid hormone on the extracellular domain of integrin αvβ3 on endothelial cells has revealed the complexity of the nongenomic regulation of angiogenesis by the hormone. From αvβ3, the hormone directs transcription of specific vascular growth factor genes, regulates growth factor receptor/growth factor interactions and stimulates endothelial cell migration to a vitronectin cue; these actions are implicated experimentally in tumor‐relevant angiogenesis and angioproliferative pulmonary hypertension. Derived from L‐thyroxine (T4), tetraiodothyroacetic acid (tetrac) can be covalently bound to a polymer and as Nanotetrac acts exclusively at the hormone receptor on αvβ3 to block actions of T4 and 3,5,3′‐triiodo‐L‐thyronine (T3) on angiogenesis. Other antiangiogenic actions of Nanotetrac include disruption of crosstalk between integrin αvβ3 and adjacent cell surface vascular growth factor receptors, resulting in disordered vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF; FGF2) actions at their respective plasma membrane receptors. From αvβ3, Nanotetrac also downregulates expression of VEGFA and epidermal growth factor receptor (EGFR) genes, upregulates transcription of the angiogenesis suppressor gene, thrombospondin 1 (THBS1; TSP1) and decreases cellular abundance of Ang‐2 protein and matrix metalloproteinase‐9. Existence of this receptor provides new insights into the multiple mechanisms by which thyroid hormone and hormone analogs may regulate angiogenesis at the molecular level. The receptor also offers pharmacological opportunities for interruption of pathological angiogenesis via integrin αvβ3. © 2016 American Physiological Society. Compr Physiol 6:353‐362, 2016.

Comprehensive Physiology offers downloadable PowerPoint presentations of figures for non-profit, educational use, provided the content is not modified and full credit is given to the author and publication.

Download a PowerPoint presentation of all images


Figure 1. Figure 1. Schematic diagram of mechanisms of integrin‐dependent, nongenomic actions of T4, T3, and a thyroid hormone antagonist, Nanotetrac, on angiogenesis. T4 and T3 are proangiogenic at the integrin of endothelial cells by amplifying vascular growth factor signals (VEGF, bFGF, PDGF, and EGF) at the growth factor receptors that are adjacent to αvβ3. Nanotetrac is antiangiogenic by multiple mechanisms. The agent (A) inhibits amplification by T4 and T3 of vascular growth factor signals and (B) disrupts specific growth factor interactions with growth factor receptor in the absence of T4 and T3. Nanotetrac also blocks the proangiogenic actions of bradykinin, Ang II, and LPS by mechanisms that appear to depend upon αvβ3. Local release of Ang‐2 and MMP‐9 is an anticipatory step in angiogenesis and is also decreased by Nanotetrac, but the mechanism is not yet known. Not shown is the antiangiogenic effect of Nanotetrac involving modulation of transcription of angiogenesis‐relevant genes; these genes are listed in Table .


Figure 1. Schematic diagram of mechanisms of integrin‐dependent, nongenomic actions of T4, T3, and a thyroid hormone antagonist, Nanotetrac, on angiogenesis. T4 and T3 are proangiogenic at the integrin of endothelial cells by amplifying vascular growth factor signals (VEGF, bFGF, PDGF, and EGF) at the growth factor receptors that are adjacent to αvβ3. Nanotetrac is antiangiogenic by multiple mechanisms. The agent (A) inhibits amplification by T4 and T3 of vascular growth factor signals and (B) disrupts specific growth factor interactions with growth factor receptor in the absence of T4 and T3. Nanotetrac also blocks the proangiogenic actions of bradykinin, Ang II, and LPS by mechanisms that appear to depend upon αvβ3. Local release of Ang‐2 and MMP‐9 is an anticipatory step in angiogenesis and is also decreased by Nanotetrac, but the mechanism is not yet known. Not shown is the antiangiogenic effect of Nanotetrac involving modulation of transcription of angiogenesis‐relevant genes; these genes are listed in Table .
References
 1.Al Husseini A, Bagnato G, Farkas L, Gomez‐Arroyo J, Farkas D, Mizuno S, Kraskauskas D, Abbate A, Van Tassel B, Voelkel NF, Bogaard HJ. Thyroid hormone is highly permissive in angioproliferative pulmonary hypertension in rats. Eur Respir J 41: 104‐114, 2013.
 2.Balaji S, LeSaint M, Bhattacharya SS, Moles C, Dhamija Y, Kidd M, Le LD, King A, Shaaban A, Crombleholme TM, Bollyky P, Keswani SG. Adenoviral‐mediated gene transfer of insulin‐like growth factor 1 enhances wound healing and induces angiogenesis. J Surg Res 190: 367‐377, 2014.
 3.Bergh JJ, Lin HY, Lansing L, Mohamed SN, Davis FB, Mousa S, Davis PJ. Integrin alphaVbeta3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen‐activated protein kinase and induction of angiogenesis. Endocrinology 146: 2864‐2871, 2005.
 4.Bharali DJ, Yalcin M, Davis PJ, Mousa SA. Tetraiodothyroacetic acid‐conjugated PLGA nanoparticles: A nanomedicine approach to treat drug‐resistant breast cancer. Nanomedicine (Lond) 8: 1943‐1954, 2013.
 5.Bruce D, Tan PH. Vascular endothelial growth factor receptors and the therapeutic targeting of angiogenesis in cancer: Where do we go from here? Cell Commun Adhes 18: 85‐103, 2011.
 6.Cayrol F, Diaz Flaque MC, Fernando T, Yang SN, Sterle HA, Bolontrade M, Amoros M, Isse B, Farias RN, Ahn H, Tian YF, Tabbo F, Singh A, Inghirami G, Cerchietti L, Cremaschi GA. Integrin alphavbeta3 acting as membrane receptor for thyroid hormones mediates angiogenesis in malignant T cells. Blood 125: 841‐851, 2015.
 7.Chen J, Ortmeier SB, Savinova OV, Nareddy VB, Beyer AJ, Wang D, Gerdes AM. Thyroid hormone induces sprouting angiogenesis in adult heart of hypothyroid mice through the PDGF‐Akt pathway. J Cell Mol Med 16: 2726‐2735, 2012.
 8.Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis 10: 133‐140, 2007.
 9.Chen Q, Jin M, Yang F, Zhu J, Xiao Q, Zhang L. Matrix metalloproteinases: Inflammatory regulators of cell behaviors in vascular formation and remodeling. Mediators Inflamm 2013: 928315, 2013.
 10.Cheng SY, Leonard JL, Davis PJ. Molecular aspects of thyroid hormone actions. Endocr Rev 31: 139‐170, 2010.
 11.Chilian WM, Wangler RD, Peters KG, Tomanek RJ, Marcus ML. Thyroxine‐induced left ventricular hypertrophy in the rat. Anatomical and physiological evidence for angiogenesis. Circ Res 57: 591‐598, 1985.
 12.Chiorean R, Berindan‐Neagoe I, Braicu C, Florian IS, Leucuta D, Crisan D, Cernea V. Quantitative expression of serum biomarkers involved in angiogenesis and inflammation, in patients with glioblastoma multiforme: Correlations with clinical data. Cancer Biomark 14: 185‐194, 2014.
 13.Cohen K, Flint N, Shalev S, Erez D, Baharal T, Davis PJ, Hercbergs A, Ellis M, Ashur‐Fabian O. Thyroid hormone regulates adhesion, migration and matrix metalloproteinase 9 activity via alphavbeta3 integrin in myeloma cells. Oncotarget 5: 6312‐6322, 2014.
 14.Davis FB, Mousa SA, O'Connor L, Mohamed S, Lin HY, Cao HJ, Davis PJ. Proangiogenic action of thyroid hormone is fibroblast growth factor‐dependent and is initiated at the cell surface. Circ Res 94: 1500‐1506, 2004.
 15.Davis PJ, Davis FB, Mousa SA, Luidens MK, Lin HY. Membrane receptor for thyroid hormone: Physiologic and pharmacologic implications. Annu Rev Pharmacol Toxicol 51: 99‐115, 2011.
 16.Davis PJ, Glinsky GV, Lin HY, Incerpi S, Davis FB, Mousa SA, Tang HY, Hercbergs A, Luidens MK. Molecular mechanisms of actions of formulations of the thyroid hormone analogue, tetrac, on the inflammatory response. Endocr Res 38: 112‐118, 2013.
 17.Davis PJ, Lin HY, Tang HY, Davis FB, Mousa SA. Adjunctive input to the nuclear thyroid hormone receptor from the cell surface receptor for the hormone. Thyroid 23: 1503‐1509, 2013.
 18.de Mello RA, Madureira P, Carvalho LS, Araujo A, O'Brien M, Popat S. EGFR and KRAS mutations, and ALK fusions: Current developments and personalized therapies for patients with advanced non‐small‐cell lung cancer. Pharmacogenomics 14: 1765‐1777, 2013.
 19.De Vito P, Balducci V, Leone S, Percario Z, Mangino G, Davis PJ, Davis FB, Affabris E, Luly P, Pedersen JZ, Incerpi S. Nongenomic effects of thyroid hormones on the immune system cells: New targets, old players. Steroids 77: 988‐995, 2012.
 20.Dedecjus M, Kolomecki K, Brzezinski J, Adamczewski Z, Tazbir J, Lewinski A. Influence of L‐thyroxine administration on poor‐platelet plasma VEGF concentrations in patients with induced short‐term hypothyroidism, monitored for thyroid carcinoma. Endocr J 54: 63‐69, 2007.
 21.Dobrucki LW, Meoli DF, Hu J, Sadeghi MM, Sinusas AJ. Regional hypoxia correlates with the uptake of a radiolabeled targeted marker of angiogenesis in rat model of myocardial hypertrophy and ischemic injury. J Physiol Pharmacol 60(Suppl 4): 117‐123, 2009.
 22.El Eter E, Rabee H, Alkayali A, Mousa S. Role of thyroid hormone analogs in angiogenesis and the development of collaterals in rabbit hind limb ischemia model. J Thromb Thrombolysis 5 (Suppl. 1): 375, 2007.
 23.Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL. Activation of vascular endothelial growth factor gene transcription by hypoxia‐inducible factor 1. Mol Cell Biol 16: 4604‐4613, 1996.
 24.Glinskii AB, Glinsky GV, Lin HY, Tang HY, Sun M, Davis FB, Luidens MK, Mousa SA, Hercbergs AH, Davis PJ. Modification of survival pathway gene expression in human breast cancer cells by tetraiodothyroacetic acid (tetrac). Cell Cycle 8: 3562‐3570, 2009.
 25.Hall H, Hubbell JA. Matrix‐bound sixth Ig‐like domain of cell adhesion molecule L1 acts as an angiogenic factor by ligating alphavbeta3‐integrin and activating VEGF‐R2. Microvasc Res 68: 169‐178, 2004.
 26.Haubner R, Maschauer S, Prante O. PET radiopharmaceuticals for imaging integrin expression: Tracers in clinical studies and recent developments. Biomed Res Int 2014: 871609, 2014.
 27.Heidegger I, Kern J, Ofer P, Klocker H, Massoner P. Oncogenic functions of IGF1R and INSR in prostate cancer include enhanced tumor growth, cell migration and angiogenesis. Oncotarget 5: 2723‐2735, 2014.
 28.Incerpi S, Hsieh MT, Lin HY, Cheng GY, De Vito P, Fiore AM, Ahmed RG, Salvia R, Candelotti E, Leone S, Luly P, Pedersen JZ, Davis FB, Davis PJ. Thyroid hormone inhibition in L6 myoblasts of IGF‐I‐mediated glucose uptake and proliferation: New roles for integrin alphavbeta3. Am J Physiol Cell Physiol 307: C150‐C161, 2014.
 29.Jiang JY, Miyabayashi K, Nottola SA, Umezu M, Cecconi S, Sato E, Macchiarelli G. Thyroxine treatment stimulated ovarian follicular angiogenesis in immature hypothyroid rats. Histol Histopathol 23: 1387‐1398, 2008.
 30.Johnson LL, Schofield L, Donahay T, Bouchard M, Poppas A, Haubner R. Radiolabeled arginine‐glycine‐aspartic acid peptides to image angiogenesis in swine model of hibernating myocardium. JACC Cardiovasc Imaging 1: 500‐510, 2008.
 31.Kalyanaraman H, Schwappacher R, Joshua J, Zhuang S, Scott BT, Klos M, Casteel DE, Frangos JA, Dillmann W, Boss GR, Pilz RB. Nongenomic thyroid hormone signaling occurs through a plasma membrane‐localized receptor. Sci Signal 7: ra48, 2014.
 32.Kang CM, Koo HJ, Lee S, Lee KC, Oh YK, Choe YS. 64Cu‐Labeled tetraiodothyroacetic acid‐conjugated liposomes for PET imaging of tumor angiogenesis. Nucl Med Biol 40: 1018‐1024, 2013.
 33.Karar J, Maity A. PI3K/AKT/mTOR pathway in angiogenesis. Front Mol Neurosci 4: 51, 2011.
 34.Koh MY, Spivak‐Kroizman TR, Powis G. HIF‐1alpha and cancer therapy. Recent Results Cancer Res 180: 15‐34, 2010.
 35.Kumar AH, Martin K, Turner EC, Buneker CK, Dorgham K, Deterre P, Caplice NM. Role of CX3CR1 receptor in monocyte/macrophage driven neovascularization. PLoS One 8: e57230, 2013.
 36.Leonard JL. Non‐genomic actions of thyroid hormone in brain development. Steroids 73: 1008‐1012, 2008.
 37.Li X, Feng Y, Liu J, Feng X, Zhou K, Tang X. Epigallocatechin‐3‐gallate inhibits IGF‐I‐stimulated lung cancer angiogenesis through downregulation of HIF‐1alpha and VEGF expression. J Nutrigenet Nutrigenomics 6: 169‐178, 2013.
 38.Li YQ, Tao KS, Ren N, Wang YH. Effect of c‐fos antisense probe on prostaglandin E2‐induced upregulation of vascular endothelial growth factor mRNA in human liver cancer cells. World J Gastroenterol 11: 4427‐4430, 2005.
 39.Lin HY, Shih A, Davis FB, Davis PJ. Thyroid hormone promotes the phosphorylation of STAT3 and potentiates the action of epidermal growth factor in cultured cells. Biochem J 338 (Pt 2): 427‐432, 1999.
 40.Lin HY, Su YF, Hsieh MT, Lin S, Meng R, London D, Lin C, Tang HY, Hwang J, Davis FB, Mousa SA, Davis PJ. Nuclear monomeric integrin alphav in cancer cells is a coactivator regulated by thyroid hormone. FASEB J 27: 3209‐3216, 2013.
 41.Lin HY, Sun M, Tang HY, Lin C, Luidens MK, Mousa SA, Incerpi S, Drusano GL, Davis FB, Davis PJ. L‐Thyroxine vs. 3,5,3′‐triiodo‐L‐thyronine and cell proliferation: Activation of mitogen‐activated protein kinase and phosphatidylinositol 3‐kinase. Am J Physiol Cell Physiol 296: C980‐C991, 2009.
 42.Liu R, Li Z, Bai S, Zhang H, Tang M, Lei Y, Chen L, Liang S, Zhao YL, Wei Y, Huang C. Mechanism of cancer cell adaptation to metabolic stress: Proteomics identification of a novel thyroid hormone‐mediated gastric carcinogenic signaling pathway. Mol Cell Proteomics 8: 70‐85, 2009.
 43.Liu X, Zheng N, Shi YN, Yuan J, Li L. Thyroid hormone induced angiogenesis through the integrin alphavbeta3/protein kinase D/histone deacetylase 5 signaling pathway. J Mol Endocrinol 52: 245‐254, 2014.
 44.Makino A, Suarez J, Wang H, Belke DD, Scott BT, Dillmann WH. Thyroid hormone receptor‐beta is associated with coronary angiogenesis during pathological cardiac hypertrophy. Endocrinology 150: 2008‐2015, 2009.
 45.Mas‐Moruno C, Rechenmacher F, Kessler H. Cilengitide: The first anti‐angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem 10: 753‐768, 2010.
 46.Matsuo Y, Takeyama H, Guha S. Cytokine network: New targeted therapy for pancreatic cancer. Curr Pharm Des 18: 2416‐2419, 2012.
 47.Meng R, Tang HY, Westfall J, London D, Cao JH, Mousa SA, Luidens M, Hercbergs A, Davis FB, Davis PJ, Lin HY. Crosstalk between integrin alphavbeta3 and estrogen receptor‐alpha is involved in thyroid hormone‐induced proliferation in human lung carcinoma cells. PLoS One 6: e27547, 2011.
 48.Middleton K, Jones J, Lwin Z, Coward JI. Interleukin‐6: An angiogenic target in solid tumours. Crit Rev Oncol Hematol 89: 129‐139, 2014.
 49.Moreno M, de Lange P, Lombardi A, Silvestri E, Lanni A, Goglia F. Metabolic effects of thyroid hormone derivatives. Thyroid 18: 239‐253, 2008.
 50.Mousa SA, Bergh JJ, Dier E, Rebbaa A, O'Connor LJ, Yalcin M, Aljada A, Dyskin E, Davis FB, Lin HY, Davis PJ. Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor. Angiogenesis 11: 183‐190, 2008.
 51.Mousa SS, Davis FB, Davis PJ, Mousa SA. Human platelet aggregation and degranulation is induced in vitro by L‐thyroxine, but not by 3,5,3′‐triiodo‐L‐thyronine or diiodothyropropionic acid (DITPA). Clin Appl Thromb Hemost 16: 288‐293, 2010.
 52.Mousa SA, Davis FB, Mohamed S, Davis PJ, Feng X. Pro‐angiogenesis action of thyroid hormone and analogs in a three‐dimensional in vitro microvascular endothelial sprouting model. Int Angiol 25: 407‐413, 2006.
 53.Mousa SA, Lin HY, Tang HY, Hercbergs A, Luidens MK, Davis PJ. Modulation of angiogenesis by thyroid hormone and hormone analogues: Implications for cancer management. Angiogenesis 17: 463‐469, 2014.
 54.Mousa SA, O'Connor LJ, Bergh JJ, Davis FB, Scanlan TS, Davis PJ. The proangiogenic action of thyroid hormone analogue GC‐1 is initiated at an integrin. J Cardiovasc Pharmacol 46: 356‐360, 2005.
 55.Mousa SA, O'Connor L, Davis FB, Davis PJ. Proangiogenesis action of the thyroid hormone analog 3,5‐diiodothyropropionic acid (DITPA) is initiated at the cell surface and is integrin mediated. Endocrinology 147: 1602‐1607, 2006.
 56.Mousa SA, Thangirala S, Lin HY, Tang HY, Glinsky GV, Davis PJ. MicroRNA‐21 and microRNA‐15A expression in human breast cancer (MDA‐MB‐231) cells exposed to nanoparticulate tetraiodothyroacetic acid (Nanotetrac). 2014 Meeting of the Endocrine Society 2014; Abstract SUN‐0472.
 57.Mousa SA, Yalcin M, Bharali DJ, Meng R, Tang HY, Lin HY, Davis FB, Davis PJ. Tetraiodothyroacetic acid and its nanoformulation inhibit thyroid hormone stimulation of non‐small cell lung cancer cells in vitro and its growth in xenografts. Lung Cancer 76: 39‐45, 2012.
 58.Nagy JA, Dvorak AM, Dvorak HF. Vascular hyperpermeability, angiogenesis, and stroma generation. Cold Spring Harb Perspect Med 2: a006544, 2012.
 59.Oki N, Matsuo H, Nakago S, Murakoshi H, Laoag‐Fernandez JB, Maruo T. Effects of 3,5,3′‐triiodothyronine on the invasive potential and the expression of integrins and matrix metalloproteinases in cultured early placental extravillous trophoblasts. J Clin Endocrinol Metab 89: 5213‐5221, 2004.
 60.Omar HA, Arafa el SA, Salama SA, Arab HH, Wu CH, Weng JR. OSU‐A9 inhibits angiogenesis in human umbilical vein endothelial cells via disrupting Akt‐NF‐kappaB and MAPK signaling pathways. Toxicol Appl Pharmacol 272: 616‐624, 2013.
 61.Owen JL, Mohamadzadeh M. Macrophages and chemokines as mediators of angiogenesis. Front Physiol 4: 159, 2013.
 62.Palenski TL, Gurel Z, Sorenson CM, Hankenson KD, Sheibani N. Cyp1B1 expression promotes angiogenesis by suppressing NF‐kappaB activity. Am J Physiol Cell Physiol 305: C1170‐C1184, 2013.
 63.Pathak A, Sinha RA, Mohan V, Mitra K, Godbole MM. Maternal thyroid hormone before the onset of fetal thyroid function regulates reelin and downstream signaling cascade affecting neocortical neuronal migration. Cereb Cortex 21: 11‐21, 2011.
 64.Patsenker E, Popov Y, Stickel F, Schneider V, Ledermann M, Sagesser H, Niedobitek G, Goodman SL, Schuppan D. Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology 50: 1501‐1511, 2009.
 65.Pinto M, Soares P, Ribatti D. Thyroid hormone as a regulator of tumor induced angiogenesis. Cancer Lett 301: 119‐126, 2011.
 66.Savinova OV, Liu Y, Aasen GA, Mao K, Weltman NY, Nedich BL, Liang Q, Gerdes AM. Thyroid hormone promotes remodeling of coronary resistance vessels. PLoS One 6: e25054, 2011.
 67.Schlenker EH, Hora M, Liu Y, Redetzke RA, Morkin E, Gerdes AM. Effects of thyroidectomy, T4, and DITPA replacement on brain blood vessel density in adult rats. Am J Physiol Regul Integr Comp Physiol 294: R1504‐R1509, 2008.
 68.Schmidt BM, Martin N, Georgens AC, Tillmann HC, Feuring M, Christ M, Wehling M. Nongenomic cardiovascular effects of triiodothyronine in euthyroid male volunteers. J Clin Endocrinol Metab 87: 1681‐1686, 2002.
 69.Schreier B, Gekle M, Grossmann C. Role of epidermal growth factor receptor in vascular structure and function. Curr Opin Nephrol Hypertens 23: 113‐121, 2014.
 70.Shchors K, Evan G. Tumor angiogenesis: Cause or consequence of cancer? Cancer Res 67: 7059‐7061, 2007.
 71.Shih A, Zhang S, Cao HJ, Tang HY, Davis FB, Davis PJ, Lin HY. Disparate effects of thyroid hormone on actions of epidermal growth factor and transforming growth factor‐alpha are mediated by 3′,5′‐cyclic adenosine 5′‐monophosphate‐dependent protein kinase II. Endocrinology 145: 1708‐1717, 2004.
 72.Sun CY, She XM, Qin Y, Chu ZB, Chen L, Ai LS, Zhang L, Hu Y. miR‐15a and miR‐16 affect the angiogenesis of multiple myeloma by targeting VEGF. Carcinogenesis 34: 426‐435, 2013.
 73.Swenson S, Ramu S, Markland FS. Anti‐angiogenesis and RGD‐containing snake venom disintegrins. Curr Pharm Des 13: 2860‐2871, 2007.
 74.Tomanek RJ, Busch TL. Coordinated capillary and myocardial growth in response to thyroxine treatment. Anat Rec 251: 44‐49, 1998.
 75.Tomanek RJ, Zimmerman MB, Suvarna PR, Morkin E, Pennock GD, Goldman S. A thyroid hormone analog stimulates angiogenesis in the post‐infarcted rat heart. J Mol Cell Cardiol 30: 923‐932, 1998.
 76.van der Veeken J, Oliveira S, Schiffelers RM, Storm G, van Bergen En Henegouwen PM, Roovers RC. Crosstalk between epidermal growth factor receptor‐ and insulin‐like growth factor‐1 receptor signaling: Implications for cancer therapy. Curr Cancer Drug Targets 9: 748‐760, 2009.
 77.Varner JA, Cheresh DA. Tumor angiogenesis and the role of vascular cell integrin alphavbeta3. Important Adv Oncol 1996:69‐87.
 78.Wang J, Milner R. Fibronectin promotes brain capillary endothelial cell survival and proliferation through alpha5beta1 and alphavbeta3 integrins via MAP kinase signalling. J Neurochem 96: 148‐159, 2006.
 79.Wang X, Zheng W, Christensen LP, Tomanek RJ. DITPA stimulates bFGF, VEGF, angiopoietin, and Tie‐2 and facilitates coronary arteriolar growth. Am J Physiol Heart Circ Physiol 284: H613‐H618, 2003.
 80.Wang Y, Yan W, Lu X, Qian C, Zhang J, Li P, Shi L, Zhao P, Fu Z, Pu P, Kang C, Jiang T, Liu N, You Y. Overexpression of osteopontin induces angiogenesis of endothelial progenitor cells via the avbeta3/PI3K/AKT/eNOS/NO signaling pathway in glioma cells. Eur J Cell Biol 90: 642‐648, 2011.
 81.Waters EA, Chen J, Allen JS, Zhang H, Lanza GM, Wickline SA. Detection and quantification of angiogenesis in experimental valve disease with integrin‐targeted nanoparticles and 19‐fluorine MRI/MRS. J Cardiovasc Magn Reson 10: 43, 2008.
 82.Yalcin M, Bharali DJ, Dyskin E, Dier E, Lansing L, Mousa SS, Davis FB, Davis PJ, Mousa SA. Tetraiodothyroacetic acid and tetraiodothyroacetic acid nanoparticle effectively inhibit the growth of human follicular thyroid cell carcinoma. Thyroid 20: 281‐286, 2010.
 83.Yalcin M, Bharali DJ, Lansing L, Dyskin E, Mousa SS, Hercbergs A, Davis FB, Davis PJ, Mousa SA. Tetraidothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts. Anticancer Res 29: 3825‐3831, 2009.
 84.Yalcin M, Dyskin E, Lansing L, Bharali DJ, Mousa SS, Bridoux A, Hercbergs AH, Lin HY, Davis FB, Glinsky GV, Glinskii A, Ma J, Davis PJ, Mousa SA. Tetraiodothyroacetic acid (tetrac) and nanoparticulate tetrac arrest growth of medullary carcinoma of the thyroid. J Clin Endocrinol Metab 95: 1972‐1980, 2010.
 85.Yalcin M, Lin HY, Sudha T, Bharali DJ, Meng R, Tang HY, Davis FB, Stain SC, Davis PJ, Mousa SA. Response of human pancreatic cancer cell xenografts to tetraiodothyroacetic acid nanoparticles. Horm Cancer 4: 176‐185, 2013.
 86.Yoshida T, Gong J, Xu Z, Wei Y, Duh EJ. Inhibition of pathological retinal angiogenesis by the integrin alphavbeta3 antagonist tetraiodothyroacetic acid (tetrac). Exp Eye Res 94: 41‐48, 2012.
 87.Zhang L, Cooper‐Kuhn CM, Nannmark U, Blomgren K, Kuhn HG. Stimulatory effects of thyroid hormone on brain angiogenesis in vivo and in vitro. J Cereb Blood Flow Metab 30: 323‐335, 2010.
 88.Zhang X, Xiong Z, Wu Y, Cai W, Tseng JR, Gambhir SS, Chen X. Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F‐FRGD2. J Nucl Med 47: 113‐121, 2006.
 89.Zhao D, Tu Y, Wan L, Bu L, Huang T, Sun X, Wang K, Shen B. In vivo monitoring of angiogenesis inhibition via down‐regulation of mir‐21 in a VEGFR2‐luc murine breast cancer model using bioluminescent imaging. PLoS One 8: e71472, 2013.
 90.Zheng L, Amano K, Iohara K, Ito M, Imabayashi K, Into T, Matsushita K, Nakamura H, Nakashima M. Matrix metalloproteinase‐3 accelerates wound healing following dental pulp injury. Am J Pathol 175: 1905‐1914, 2009.
 91.Zheng W, Weiss RM, Wang X, Zhou R, Arlen AM, Lei L, Lazartigues E, Tomanek RJ. DITPA stimulates arteriolar growth and modifies myocardial postinfarction remodeling. Am J Physiol Heart Circ Physiol 286: H1994‐H2000, 2004.

Contact Editor

Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite

Paul J. Davis, Thangirala Sudha, Hung‐Yun Lin, Shaker A. Mousa. Thyroid Hormone, Hormone Analogs, and Angiogenesis. Compr Physiol 2015, 6: 353-362. doi: 10.1002/cphy.c150011